174 related articles for article (PubMed ID: 37999108)
1. Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia.
Shah R; Polen-De C; McGree M; Fought A; Kumar A
Curr Oncol; 2023 Oct; 30(11):9501-9513. PubMed ID: 37999108
[TBL] [Abstract][Full Text] [Related]
2. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
3. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
Narasimhulu DM; McGree ME; Weaver AL; Jatoi A; LeBrasseur NK; Glaser GE; Langstraat CL; Block MS; Kumar A
Gynecol Oncol; 2020 Sep; 158(3):646-652. PubMed ID: 32518016
[TBL] [Abstract][Full Text] [Related]
4. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
5. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
6. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
7. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
9. Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
Martin AL; Colin-Leitzinger CM; Sinha SK; Chern JY; Peres LC
Br J Cancer; 2023 Jun; 128(12):2236-2242. PubMed ID: 37024666
[TBL] [Abstract][Full Text] [Related]
10. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
Kumar A; Moynagh MR; Multinu F; Cliby WA; McGree ME; Weaver AL; Young PM; Bakkum-Gamez JN; Langstraat CL; Dowdy SC; Jatoi A; Mariani A
Gynecol Oncol; 2016 Aug; 142(2):311-6. PubMed ID: 27235857
[TBL] [Abstract][Full Text] [Related]
11. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
16. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
[TBL] [Abstract][Full Text] [Related]
18. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
19. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Fauci JM; Whitworth JM; Schneider KE; Subramaniam A; Zhang B; Frederick PJ; Kilgore LC; Straughn JM
Gynecol Oncol; 2011 Sep; 122(3):532-5. PubMed ID: 21658751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
